Telomir Pharmaceuticals publishes preclinical AMD data for Telomir-Zn
Telomir Pharmaceuticals has announced the publication of preclinical research showing that its lead compound, Telomir-Zn, improved visual function, restored retinal architecture, and reduced mitochondrial oxidative stress in a zebrafish model of age-related macular degeneration (AMD). The findings, published in the International Journal of Molecular Sciences, represent the first peer-reviewed data linking the compound's mechanism to retinal disease biology.
The study used an accelerated retinal degeneration model in which untreated animals exhibited substantial photoreceptor loss, retinal pigment epithelium disruption, and degeneration across multiple retinal layers. After 14 days of oral Telomir-Zn treatment, histological analysis showed restoration of thickness across the outer and inner nuclear layers, the outer plexiform layer, and the ganglion cell layer. Behavioural measures of visual performance, including moving-object tracking and adaptation to light-intensity changes, also improved significantly relative to untreated controls.
Mechanism and epigenetic read-across
The mechanistic studies described in the paper centre on Telomir-Zn's ability to increase intracellular zinc while reducing labile ferrous iron. That iron depletion, the authors propose, suppresses a family of iron-dependent histone demethylases known as Jumonji C domain-containing proteins, or KDMs. The compound showed potent inhibitory activity against the KDM2, KDM5, and KDM6 families in biochemical assays, with the strongest effect against KDM5B at an IC50 of 63 nM. Because KDMs regulate gene expression through histone methylation, the company argues that modulating intracellular metal balance may shift stressed retinal cells toward programmes governing inflammation, senescence, DNA repair, and survival.
Treatment was also associated with a dose-dependent increase in relative telomeric DNA content toward levels seen in healthy wild-type animals, alongside partial restoration of DNA methylation patterns at selected ageing-associated CpG loci. The company describes these as evidence that Telomir-Zn's activity may extend to broader genomic and epigenetic processes, though the zebrafish model and the surrogate endpoints used mean further validation in mammalian systems would be expected before clinical translation could be considered.
Clinical focus and platform ambitions
Telomir's registered clinical programme remains in oncology. The company holds FDA clearance for a Phase 1/2 trial of Telomir-Zn in patients with advanced or metastatic triple-negative breast cancer, a segment where standard-of-care options remain limited and where the compound's iron-chelation mechanism has previously been linked to anti-tumour activity in cell-line experiments.
Chief executive Erez Aminov said the company sees "meaningful platform potential" for Telomir-Zn across additional cancers and other diseases, citing a common biology centred on intracellular metal homeostasis. Chief Scientific Adviser Itzchak Angel described the AMD findings as providing "an important new view of the relationship between intracellular metal balance, oxidative stress, epigenetic regulation and retinal degeneration."
The AMD market is a meaningful strategic backdrop. Wet AMD is addressed by a well-established class of anti-VEGF biologics, including ranibizumab and aflibercept, while geographic atrophy has seen recent approvals with complement-pathway inhibitors. A small-molecule candidate targeting an upstream epigenetic mechanism would occupy a different niche, but preclinical-to-clinical translation in retinal disease has historically been challenging, and no IND has been filed for the AMD indication.
For now, investors will focus on the TNBC Phase 1/2 readout as the primary near-term value inflection. The AMD publication adds mechanistic depth to Telomir-Zn's platform story, but clinical validation in any ophthalmology setting remains a distant prospect.